# RATIONALE 301: GLOBAL PHASE 3 STUDY OF TISLELIZUMAB VERSUS SORAFENIB AS FIRST-LINE TREATMENT IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA: A TRIAL-IN-PROGRESS



Shukui  $Qin^1$ , Richard S. Finn<sup>2</sup>, Masatoshi Kudo<sup>3</sup>, Tim Meyer<sup>4</sup>, Arndt Vogel<sup>5</sup>, Michel Ducreux<sup>6</sup>, Teresa Mercade Macarulla<sup>7</sup>, Gianluca Tomasello<sup>8</sup>, Frederic Boisserie<sup>9</sup>, Jeannie Hou<sup>9</sup>, Xin Li<sup>10</sup>, James Song<sup>9</sup>, Andrew X. Zhu<sup>11</sup>

<sup>1</sup>People's Liberation Army (PLA) 81 Hospital, Nanjing, China; <sup>2</sup>University of California Los Angeles, CA; <sup>3</sup>Department of Gastroenterology, Kindai University School of Medicine, Osaka, Japan; <sup>4</sup>University College London Cancer Institute, London, United Kingdom; <sup>5</sup>Medizinische Hochschule Hannover, Hannover, Germany; <sup>6</sup>Gustave Roussy, Villejuif, France; <sup>7</sup>Vall d'Hebron Institute of Oncology, Barcelona, Spain; <sup>8</sup>Azienda Istituti Ospitalieri di Cremona, Cremona, Italy; <sup>9</sup>BeiGene (Beijing) Co., Ltd., Beijing, China; <sup>11</sup>Harvard Medical School, Massachusetts General Hospital Cancer Center, Boston, MA


Poster Number: 776TiP

European Society for Medical Oncology Congress 19–23 October 2018, Munich, Germany

#### BACKGROUND

- Hepatocellular carcinoma (HCC) is a leading cause of cancer-related death,<sup>1</sup> with more than two-thirds of patients presenting with advanced disease at diagnosis<sup>2</sup>
- The multitargeted tyrosine kinase inhibitor sorafenib is currently the only globally approved first-line treatment for advanced HCC<sup>3</sup>; however, it has shown only modest efficacy in HCC and is difficult for patients to tolerate<sup>4</sup>
- Monoclonal antibodies against the immune checkpoint inhibitory receptor programmed cell death-1 (PD-1) have demonstrated antitumor activity across multiple malignancies,<sup>5</sup> including HCC<sup>6,7</sup>
- Tislelizumab (also known as BGB-A317) is a humanized, IgG4 monoclonal antibody with high affinity and binding specificity for PD-1
- Tislelizumab was specifically engineered to minimize binding to FcγR on macrophages, thereby abrogating antibody-dependent T-cell clearance, a potential mechanism of resistance to anti-PD-1 therapy (Figure 1)
- In a first-in-human, phase 1A/1B study (NCT02407990), single-agent tislelizumab was generally well tolerated and showed evidence of antitumor activity in patients with advanced solid tumors, including HCC.8-12 Phase 2 and 3 studies in patients with solid tumors are ongoing
- A recommended phase 3 dose of 200 mg administered intravenously (IV) every 3 weeks (Q3W) has been established for tislelizumab

Figure 1: Lack of FcyR Binding Prevents Macrophage-Mediated T-Cell Clearance



Abbreviations: Ab, antibody; CD, cluster of differentiation; FcyR, Fc-gamma receptor; mAb, monoclonal antibody; MHC, major

histocompatibility complex; PD-1, programmed cell death-1; PD-L1, programmed death-ligand 1.


#### METHODS

#### Overall Design and Study Objectives

- RATIONALE 301 is a global, phase 3, randomized, multicenter study (NCT03412773) designed to evaluate the efficacy and safety of tislelizumab compared with sorafenib as a first-line treatment of advanced HCC (Figure 2)
- The primary objective will be to compare overall survival (OS) between the two treatment groups
- Objective response rate (ORR), as assessed by blinded independent review committee per RECIST v1.1, is a key secondary objective
- Other key secondary objectives will include a comparison of tislelizumab and sorafenib in terms of various efficacy assessments (progression-free survival [PFS], duration of response [DoR], time to progression [TTP], disease control rate [DCR], and clinical benefit rate [CBR]), measures of health-related quality of life, and safety and tolerability
- Approximately 640 patients will be enrolled globally

#### **Study Population**

- Adult patients, aged ≥18 years, will be enrolled if they have:
- Unresectable, histologically confirmed HCC
- An Eastern Cooperative Oncology Group (ECOG) score ≤1 and Child-Pugh A classification
- Barcelona Clinic Liver Cancer (BCLC) Stage C disease or BCLC Stage B disease, are not amenable to or have relapsed after locoregional therapy, and are not amenable to a curative treatment approach
- Not received prior systemic therapy
- Patients will be excluded if they have:
- Known fibrolamellar HCC, sarcomatoid HCC, or mixed cholangiocarcinoma and HCC histology
- Tumor thrombus involving the main trunk of the portal vein or inferior vena cava
- Received loco-regional therapy to the liver or any prior immunotherapy within 28 days prior to randomization, or any Chinese herbal medicine or patent medicine used to control cancer within 14 days of randomization
- Grade 2 or higher hepatic encephalopathy (at screening or prior history)
- Pericardial effusion, uncontrollable pleural effusion, or clinically significant ascites at screening



Randomization stratified by: macrovascular invasion (present vs absent); extrahepatic spread (present vs absent); ECOG PS (0 vs 1); etiology (HCV vs other [includes HBV]); geography (Asia vs Japan vs Rest of World).

\*The initial infusion (Cycle 1, Day 1) will be administered over 60 minutes; if well tolerated, subsequent infusions may be administered over 30 minutes. After tislelizumab infusion, patients will be monitored for 2 hours during Cycles 1 and 2, and for ≥30 minutes from

<sup>†</sup>Treatment beyond the initial investigator-assessed disease progression will be permitted in both treatment arms if pseudo progression is suspected or there is reasonable belief that the patient could derive benefit from the treatment. Abbreviations: BID, twice daily; ECOG PS, Eastern Cooperative Oncology Group performance status; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; IV, intravenously; PO, orally; Q3W, once every 3 weeks; R, randomization

#### TREATMENT

- Patients will be randomized 1:1 to receive tislelizumab 200 mg IV Q3W or sorafenib 400 mg orally twice daily, with randomization stratified by the presence of macrovascular invasion, the presence of extrahepatic spread, ECOG performance status, etiology, and geography
- Treatment will be administered until disease progression, intolerable toxicity, or treatment discontinuation for other reasons

## STUDY ASSESSMENTS AND STATISTICAL ANALYSIS

- The primary efficacy endpoint of OS for tislelizumab and sorafenib are compared in a stratified log-rank test
- Secondary endpoints (such as ORR, PFS, DoR, and TTP assessed by a blinded independent review committee) will be evaluated for treatment comparisons
- Tumor response will be evaluated every 9 weeks during Year 1 and every 12 weeks from Year 2 onwards, in accordance with RECIST v1.1
- Safety and tolerability (a secondary endpoint) will be assessed by monitoring adverse events (AEs), including immune-related AEs, and through physical examinations, vital signs, and electrocardiograms
- The European Organisation for Research and Treatment of Cancer Quality of Life Cancer Questionnaire-Hepatocellular Carcinoma 18 Questions (EORTC QLQ-HCC18) and European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 will be used to assess health-related quality of life between the two treatment arms using a mixed model. The European Quality of Life 5-Dimensions will also be summarized

#### REFERENCES

- 1. Torre LA, Bray F, Siegel RL, et al. Global Cancer Statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108.
- 2. Kim DY, Han K-H. Epidemiology and surveillance of hepatocellular carcinoma. *Liver Cancer.* 2012;1(1):2–14.
- 3. Keating GM. Sorafenib: A review in hepatocellular carcinoma. Target Oncol. 2017;12(2):243-253.
- 4. Samonakis DN, Kouroumalis EA. Systemic treatment for hepatocellular carcinoma: Still unmet expectations. World J Hepatol. 2017;9(2):80-90.
- Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443-2454.
- 6. El-Khoueiry AB, Sangro B, Yau T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet. 2017;389(10088):2492–2502
- 7. Zhu AX, Finn RS, Edeline J, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol. 2018;19(7):940–952.
- 8. Desai J, Markman B, Sandhu SK, et al. Updated safety, efficacy, and pharmacokinetics (PK) results from the phase I study of BGB-A317, an anti-programmed death-1 (PD-1) mAb in patients with advanced solid tumors. J Immunother Cancer. 2016;4(suppl 1):P154
- 9. ClinicalTrials.gov. [Internet]. Bethesda (MD): National Library of Medicine (US). 2018 January 26 . Identifier NCT03412773, Phase 3 study of BGB-A317 versus sorafenib in patients with unresectable HCC. Available from: https://clinicaltrials.gov/ct2/ show/NCT03412773. Accessed: April 13, 2018.
- 10. ClinicalTrials.gov. [Internet]. Bethesda (MD): National Library of Medicine (US). 2018 February 2 . Identifier NCT03419897, Study of BGB-A317 in patients with previously treated unresectable HCC. Available from: https://clinicaltrials.gov/ct2/show/ NCT03419897. Accessed: April 13, 2018.
- 11. ClinicalTrials.gov. [Internet]. Bethesda (MD): National Library of Medicine (US). 2017 December 2 . Identifier NCT03358875, Comparison of efficacy and safety of anti-PD-1 antibody BGB-A317 versus docetaxel as treatment in the second- or third-line setting in patients with NSCLC. Available from: https://clinicaltrials.gov/ct2/show/NCT03358875. Accessed: April 13, 2018.
- 12. ClinicalTrials.gov. [Internet]. Bethesda (MD): National Library of Medicine (US). 2018 February 13 . Identifier NCT03430843, A study of BGB-A317 versus chemotherapy as second line treatment in patients with advanced esophageal squamous cell carcinoma. Available from: https://clinicaltrials.gov/ct2/show/NCT03430843. Accessed: April 13, 2018.

### ACKNOWLEDGMENTS

The authors wish to acknowledge the investigative center study staff, the study patients, and their families BeiGene, Ltd. provided financial support for this presentation including writing and editorial assistance by Regina Switzer, PhD, and Aarati Rai, PhD (SuccinctChoice Medical Communications, Chicago, IL).

Copies of this poster obtained through Quick Response (QR) Code are for personal use only and may not be reproduced without permission from the author of this poster.

